Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)
January 24, 2023
January 24, 2023
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
January 5, 2023
January 5, 2023
Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive
November 30, 2022
November 30, 2022
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
November 7, 2022
November 7, 2022
MedinCell signs a licence agreement with the Medicines Patent Pool to fight malaria transmission, as part of its global health mission
September 13, 2022
September 13, 2022
Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology
August 29, 2022
August 29, 2022
MedinCell: inclusion of first participants in new Covid-19 prophylaxis clinical trial SAIVE
March 28, 2022
March 28, 2022
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
September 1, 2021
September 1, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
June 14, 2021
June 14, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
